AbbVie Secures EMA Recommendation for ELAHERE® to Treat Platinum-Resistant Ovarian Cancer

AbbVie (NYSE: ABBV) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the marketing authorization of mirvetuximab soravtansine (ELAHERE®). This drug is designed to treat adult patients with folate receptor alpha (FRα)-positive, platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer who have previously undergone one to three treatment regimens.

Ovarian cancer is often diagnosed at a late stage, requiring surgery and platinum-based chemotherapy. However, many patients develop resistance to platinum-based therapies, creating an urgent need for alternative treatments. The CHMP's recommendation is based on results from the Phase 3 MIRASOL clinical trial, which compared mirvetuximab soravtansine to standard chemotherapy options, demonstrating promising efficacy and safety.

AbbVie’s acquisition of ImmunoGen, which originally developed the drug, has positioned the company to make significant strides in treating platinum-resistant ovarian cancer across Europe. Mirvetuximab soravtansine received full FDA approval in the U.S. in March 2024, and submissions are pending in other countries.

Ovarian cancer remains one of the deadliest gynecological cancers, with more than 320,000 new cases worldwide in 2022. Standard treatments like platinum-based chemotherapy often fail due to resistance, making innovative solutions like mirvetuximab soravtansine essential.